Background; This report presents results from the acute treatment phase of a clinical trial designed to confirm efficacy
risk for school failure and dropout (Simeon, 1989) and for suicide (Brcnt, 1993; Levy et aI., 1992; Pfeffer et al., 1991) . Age at time of recogn icion of first depressive episode appears to be decreasing (Kovacs and Gastonis, 1994) ; this finding suggests that many individuals experience their first episodes of depression as children or adolescents.
Much has been written about the use of antidepressants in children with various mood and anxiety disorders, but there have been few adequately powered controlled clinical trials in the area of MOD. Controlled studies of tricyclic antidepressant treatment for children and adolescents with depression failcd [() produce a replicable pattern of efficacy (Geller et aI., 1999) . In a controlled, double-blind clinical trial, vcnlafaxinc was not superior to placebo for treatment of depression in children and adolescents (Mandoki et al., 1997) .
For first-line acute treacment of MOD in children and adolescents, the AACAP recommends psychotherapy, treatment with a selective serotonin rcuptake inhibitor '"len ,. ,.
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(SSRl), or both combined, depending on the patient, the patient's circumstances, and the severity of disease. SSRls are recommended because of their relative safety, low lethality on overdose, and ease of administration (AACAP, 1998) . The Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder recommends using fluoxetine, paroxetine, or sertraline first when medication is warranted for child and adolescent MDD (Hughes et al., 1999) .
In an open-label trial, sertraline appeared to be efficacious for the treatment of MOD in patients between 12 and 20 years of age (Ambrosini et al., 1999) . However, this finding has not yet been confirmed in a placebo-controlled, double-blind clinical trial. Paroxetine was reported to be effective for the treatment of MDD in children and in adolescents in an open-label trial (Rey-Sanchez et aI., 1997) . Paroxetine was also statistically significantly superior to placebo on one of two primary efficacy measures in a controlled clinical [rial of treatment for adolescents (but not children) with MOD (Keller et al., 2001) .
Efficacy of fluoxetinc in the treatment of pediatric depression has been demonstrated in a double-blind, placebo-controlled study (Emslie et al., 1997) . This study demonstrated that a fixed dose (20 mg/day) of fluoxetine was efficacious and well tolerated. Other reports have indicated that children and adolescents may require fluoxetine doses greater than 20 mg/day (Colle et aI., 1994; Jain et al., 1992; Simeon et aI., 1990) . One naturalistic study indicated that doses less than 20 mg may be effective for some adolescents (Boulos et al. 1992 ).
This report presents safety and efficacy data from the 9-week acute treatment phase of a clinical trial designed to confirm and extend the findings of previous studies of fluoxetine in children and adolescents with MDD. Diseasespecific and broad-based eHicacy measures were evaluated. The safety of fluoxnine treatment was assessed by examining treatment-emergent solicited and nonsolicited adverse events and vital signs.
METHOD

Study Design
A multiphase study was designed [0 examine efficacy and rolerabilit}, of various dosing strategics for fllloxetine trearment of depressed children and adolescents. The inirial phase, reported here, was designed to confirm a previous report rhat fllloxetine 20 mg was effective and well toleta[ed fot acure treafmem of pediatric MOD.
To obrain the most teliable assessment of parients' condition, this study incorporated an extensive diagnostic evaluation period requiring three independent diagnosric interviews (visits 1,2, and 3 [week -3, -2, and -I]). The Diagnostic Interview for Children and Adolescems (DICA) (or the MissouriA<;sessment of Genetics Interview for Children [MAGIC] , which incorporates it) was administered to all enrolled patiems and their parents at each interview, to establish the diagnosis ofMDD. (Only the questions present in both the DlCAand MAGIC were used for this srudy.) The interviews wete conducted by three difterem interviewers, at leasr one of whom was a psychiatrist. Other interviewers were qualified and experienced pediattic health care pcotessionals. Each imerviewer had access to infotmation from previous interviews for each patient. This was done to ensure the accutacy and completeness of the informacion gathered during the evaluation process. Final diagnoses were detetmined after visit 3. Patients and their parem(s) or guardian(s} were interviewed separarely. To increase imerrater teliability. interviewers received ttaining in the use of the OICA or MAGIC. No drug was administeted during the evaluation period. This was followed by a single-blind, I-week, placebo lead-in petiod (between visits 3 and 4 [week -1 and week 0]). Patients who responded during this petiod (defined as~o% decrease in Children's Depression Rating ScaleRevised. [CDRS-Rl or a Oinician's Global Impressions lCGIJ Improvement score of I or 2) wete discontinued from the study. Those who did not respond during rhe placebo lead-in wete assigned to treatment groups by means of a oompuret-generared randomization sequena:. Randomization was stratified by gender and age category across invesrigarive sites.
Patiems in the placebo trearment group wete instrucred to take three capsules, which contained placebo, once daily for 9 weeks. Padents in the Auoxetine rreatment group were also insttucted to rake thtee capsules daily. Fot the first week, these consisted of two placebo capsules and a capsule comaining 10 mg of Ruoxetine. For weeks 2 through 9, one capsule comained placebo and two capsules contained 10 mg of Auoxetine each.
Aftet teceiving study medication, patiems teturned tor efficacy and advetse event assessments at weeks 1,2, 3, 5, 7, and 9 (visits 5 through 10).
Participants
Eligibility requirements fot participation in the trial included primary diagnosis of nonpsychodc MDD (single Ot tecurrent) as defined by DSM'-IVcriteriaand depressive symptoms of at least moderate severity as defined by a CDRS-R tora! score >40 and a CGI-Severity rating of <::4. All other inclusion and exclusion ctiteria ate shown in Table I . This study was conducted by IS investigators rhlOughour the United States. Study sites included academic hospitals and private tesearch psychiatric clinics. Patients wete recruited from sire patient populations, as well as by newspaper and radio advertising, with rhe goal of achieving a ttial population with a wide range of severity of MDD. This study was conducred and informed consent was obrained according co the ethical principles stated in the Declaration of Helsinki, the applicable guidelines for good clinical practice, and the applicable laws and regulations of the United States. An informed consent documem approved by the investigational review board (IRB) for each site was signed by paciems' parents or guardians. Patients may have also provided consem or assem depending on the requirements of each site's lRB.
Measurements and Procedures
Dara wete collected at week -3 and at each patiem visit by clinicians who were blinded co treatment group. Parients were assessed by patient and parent report ar each visit using the CDRS-R and CGISeverity scales, administered by qualified personnel. At each visit except visit I (week -3), patiems were also assessed with the CGIImprovement scale. Adverse event data wete collecred by two meth-EFFICACY OF FLUOXETINE JI': PEDIATRIC MDD
TABLE 1
Inclusion and Exclusion Criteria Patients were included in the study only if they met all of rhe following criteria:
• Male and female ourpatients • Children (aged 8 ro < 13 years) and adolescents (aged 13 to < 18 years) ar rhe rime of study entry • A primary psychiatric diagnosis of nonpsychoric major depressive disorder (single or recurrenr) as defined by the DSM-IVcriteria • Depressive symptoms of at least moderate severity as defined by a CDRS-R total score >40 and a CGI-Severity raring of moderate or greater • Able to swallow whole medication without difficulty • No clinically significant laboratory findings in hematology, chemistry. and urinalysis at study entry based on the judgment of the investigator • ECG wirhour clinically significant abnormalities; clinical significance was determined by invesrigator and physician inrerpteting the ECG • Educational level and degree of undemanding so that the patients and parents could communicate intelligibly with the investigator and study cootdinator; normal intelligence based on the judgment of the investigator • Patients and parents judged to be reliable who agreed to keep appointments for clinic visits and all tests and examinations required by the protocol
Patients were excluded from the study for any of the following reasons:
• Investigators and their immediate families were not petmitted to be subjects or patienrs • Persons who had previously completed or withdrawn ftom this study • Females who were pregnant. breastfeeding or who were sexually active and were not using medically acceptcd mcans of conrraceprion • Serious illness (including cardiac, hepatic, renal, respiratory, endoctinological. neurological, or hematologid disease) that was nOt stabilized so that hospitalization for treatment of that illness was likely within the next 2 months • Patients with abnormal thytoid function • Seizute disotder with a seizure occurring within the past 6 months, except for febrile seizures • Diagnosis of any of the following DSM-IV-defined disotdets: bipolar lor II disorder, sleep-wake disorder, psychotic depression (lifetime). anorexia (lifetime), bulimia (lifetime), borderline personality disorder, Ot substance abuse disorder (wirhin the past 6 months) • Patienrs with one or more first-degree relatives with bipolar I disorder • Organic brain diseases • Persons whose illness has previously failed to respond to adequate antidepressant treatmenr (at least 8 wceks' trearment within the typical maximum adult therapeutic range) • Serious suicidal risk • History of severe allergies. multiple adverse drug reactions. or known allergy to the smdy drug • Receipt of an investigational drug wirhin 30 days prior to study entry • Receipt of any behavior-altering, centrally acting. or excluded medication within 7 days prior to study entry • Documented hypersensitivity to Ruoxetine • Prior adequate treatment wirh f1uoxetine (12 weeks on a fixed dose of 20 mg or greater) • Receipt of Ruoxetine within 3 months ptior to study entry • Regular usc of other psychottopic or centrally acting drugs. including lithium and the psychostimulanrs (i.e., drugs normally prescribed for depression. mania. anxiety, insomnia, attention-deficit/hyperactiviry deficit disorder, or psychosis) within 2 weeks ptior to study entry • Use of neutoleptics during the 2 week, prior to study enrry or of depot neuroleptics within the 6 weeks prior to study entry • Use of an MAOI within 2 weeks (14 days) prior to study enrry or potenrial need to use an MAOI within 5 weeks of discontinuation of rreatmenr • Use of tryptophan. St. John's WOrt, or melatonin within 2 weeks prior to study entry • Potenrial need for rhe continuatioo or initiation of other treatmenrs for depression. including cognitive-behavioral therapy and behavioral therapy. except for suppottive therapy on an individual or family basis
Note: CDRS-R = Children's Depression Rating Scale-Revised; CGI-Severity = Clinician's Global Impres.sions-Severity scale; ECG = electrocardiogram; MAOI = monoamine oxidase inhibitot. od,. At visits 2 (week -2) through 10 (week 9). adverse events were collected afrer genetal inquiry at the beginning of each visit. Events reported by patients at this time arc referred to as "nonsolicited" adverse evenrs. At the end of visits 4 (baseline) through 10 (week 9), adverse events were collected by asking patien ts about specific symptoms listed on the Side Effecrs Checklist. These ate referred to as "solicited" adverse events. An event was considered treatment-emergent if it was new or increased in severity after baseline.
The following instruments were used to capture efficac)' and adverse
events:
The CDRS-R (Poznanski and Mokros. 19%), a clinician-rated scale used as a .screening and diagnostic rool and a measure of sever- model for this analysis included treatment, visit (wirhin-subject factor), treatment by visit interaction, investigaror, and investigaror by tteatment inreraction with an unstructured within-subject variancecovariance matrix. If the investigator by tteatment interaction was not statistically significant (p~.1), it was dropped from the model. Adverse events were analyzed by comparing the incidence of treatment-emergent nonsolicited adverse events between treatment groups. Weeks -3 to -I were defined as baseline for nonsolieited adverse events.
lrea.tment-emergent solicited adverse events &om the Side Effects Checklist were compared between tteatment groups using week 0 as baseline. An adverse event was considered treatment-emergent if it first occurred or worsened alier baseline. Changes in viral signs from baseline to endpoint were compared between Huoxetine and placebo treatment groups.
The Fisher exact test was used to compare percenrages. An ANOVA (type III sums of squares) with the term treatment in the model was u.~ed when comparing change scores or endpoint scores between treatments. Treatment by subgroup interactions were assessed for children versus adolescents, males versus females, and patients who had a &mily history of depression versus patients who did not. To resr tor a treatment by subgroup intetaction on mean change, anANOVA with treatmeIH, sub-
Statistical Analyses
Sample si7.e was designed ro derect a 20% difference between Huoxetine 20 mg and placebo in rhe proportion of patients meeting protocol-defined response criteria with approximately 80% power and a .05 significance level (two-sided). The primary efficacy measure was the CDRS-R tesponse rate. Responsc rate was prospectively defined as ã 30% decrease in CDRS-R roral score from week 0 ro endpoint (last patient visit, weeks 2 to 9). Remission was defined as an endpoint CDRS-R roral score of~28. Analyses of response and remission included only those patients treated at lea~t 2 week~with srudy drug. Thus only Huoxetine-treated parienrs who had received at least 1 week of tteamlent with 20 mg of Huoxetine were included. All other analyses, including mean change in CDRS-R from baseline to endpoint and weekly analyses, were intent-to-treat/last patient observarion carried forward. Secondary measures included changes in CDRS-R subscores and CGI-Severiry from baseline ro endpoint. For analysis of CGI-Improvement, only endpoint values were compared, since this scale inherently measures roral improvement in direct comparison with a patient's condition at baseline.
A repeated-measures analysis of variance (ANOVA) was perfotmed on the CDRS-R total score. The baseline and each postbaseline visit were included in the model as the dependent variables. The initial ity of depression in children, consisrs of 17 items scored from 1 ro 5 or 1 £0 7 (minimum score = 17).
CGI-Severity (Guy, 1976 ) is a 7-point clinician-rated scale that measures the severiry of a patiem's symptoms.
CGI-Improvement (Guy, 1976 ) is a 7-point clinician-rated scale that measures change in global patient condition from baseline.
The Hamilton Anxiety Rating Scale (HAMA) (Hamilton, 1959 ) is a clinician-rated scale that measures the severity of anxiery; it consists of 14 items, each scored 0 to 4.
The Beck Depression Inventory (BDI) (Beck and Sreer, 1984) , a patient-rared scale, assesses major symprom categories associared with depression. Scores range from 0 ro 62. The BDI was completed only by the adolescents (aged 13 to < lH years) in rhis study. The Children's Depression Invenrory (CDl) (Kovacs, 1985) is a patient-rated scale ba~ed on rhe BDI, which meamres the severiry of depression in children. Scores range from 0 to 54. The COl was completed only by the children (aged 8 to <13 years) in this srudy.
The Global Assessment of Functioning Scale (GAF) (Endicott er aI., 1976 ) is a clinician-rated instrument that assesses the patienr's current and highest level of functioning. Scores range from 1 to 90 (90 indicates good functioning in all areas).
The Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979 ) is a clinician-rated scale that assesses depressive symptoms. The MAD RS is not commonly used as a measure of depression for children and adolescents and was included as an exploratory assessmenr.
Nonsolicited adverse events were captured regardless of relationship to study medication, as actual terms and wete categorized using Other safery measures, including laboratory tesrs and electrocardiograms (ECGs), were performed at a later stage of this study and are not reporred here.
group, and the treatment by subgroup interaction in the model was performed. Fot response and solicited treatment-emergent adverse events. a Breslow-Day test for the homogeneity of odds ratios across subgroups was performed. For nonsolicited treatment-emergent advetse events, comparisons between treatments were made within subgroups.
All testS of hypotheses were considered statistically significant if the two-sided p value was less than .05. No adjusrments for multiple comparisons were made.
RESULTS
Baseline Patient Comparisons
After 2 weeks of evaluation, and a I-week placebo leadin period, 109 patients were randomly assigned to £luox-etine treatment and 110 to placebo treatment (Fig. 1 ). There were no statistically significant differences between EFFICACY OF FLUOXETINF. IN PEDIATRIC MOD treatment groups in patient demographics at baseline ( Table 2) . Randomization of patiems resulted in treatment groups that were reasonably balanced for the current comorbid conditions attention-deficitlhyperactivity disorder (ADHD), oppositional defiant disorder, and bipolar II disorder. (Patients with bi polar II disorder above threshold level were excluded from the trial.) There was less balance between groups for conduct disorder. The £luoxetine and placebo treatment groups contained three patients and one patient with conduct disorder, respectively. They also contained 5 and 16 patients with subthreshold conduct disorder, respectively.
Mean baseline scores on the CGI-Severity scale indicated patients had moderate to marked severity of illness. Patients were required to have at least moderate severity of illness (score of 4) ro bc cnrolled in this trial. Patients were also required to have CORS-R scores above 40, the cut point for depression. The mean baseline scores of 55.1 to 57.1 are well above this cut point. BOI and COl scores were not among the criteria for enrollment in this trial, and mean baseline scores on both of [[lese self-repon measures were unexpectedly low. Although mean baseline BOI scores for adolescents were above the cut point for major depression (Roberts et aI., 1991) , mean baseline cor scores for children were below the cut point for depression (Silverman and Rabian, 1999) . Given the high percentage of patients in this study who had comorbid AOHO, it may not be surprising that results of thc clinician-rated measurcs werc not reflected by the results of the patient-rated scales.
Efficacy
Compared with placebo. Huoxetinc treatment was associated with significantly greater improvement in CORS-R aftcr 1 week of trcatment and for rhe remainder of the study (Fig. 2) . Fluoxetine-treated patients had significantly greater mean change in CORS-R score at endpoint than did placebo-treated patients (p < .001) ( Table 3 ).
The 95% confidence interval for the difference between treatment groups in mean change in CORS-R is completely above zero, indicating that there is a 95% or greater probability that fluoxetine is superior to placebo in improvement on CORS-R score. Traditionally, an effect size of 0.2 is considered to be small, 0.5 medium, and 0.8 large (Cohen, 1988) . In the repeated-measures model, there was a significant treatment by visit interaction (p < .00 1) indicating treatment course over time differed for the two treatment groups. The overall treatment effect was also statistically significant (p =.006), as was thc comparison of change from baseline to endpoint between the treatment groups (p = .003).
There was no significant therapy by subgroup interaction for mean change in CORS-R bascd on age category (p = .371), gender (p = .632), or family history of depression (p = .493). Significantly more fluoxetinetreated patients (41.3%) than placebo-treated patients (19.8%) met the prospectively defined criteria for remission (p < .01).
Mean improvement in CORS-R mood and behavior subscores was also significantly greater for fluoxetinetreated patients than for placebo-treatcd patients at weeks 1 through 9 (p < .05). 'For CDRS-R, MADRS, and CGI-Severity, n =109; for HAMA, n =106; and for GAP, 11 =104. b For CDRS-R and MADRS, n =105; for HAMA, n =94; for GAP, n =86; and for CGI-Severity, n =106.
e Difference in Mean Change shows results of subtracting the mean change in the fluaxerine treatment group from the mean change in the placebo treatment group. 95% confidence intervals fat the differences are shown in parentheses below. If the entire 95% confidence interval is greater rhan zero. this indica res a 95% or greater probability rhar the mean change associared wirh Huoxetine treatment is grearer rhan the mean change associated wirh placebo.
d p Value for difference in mean change between trearment groups, derived using a type III sum of squares analysis of variance with treatment in the model. jective subscores, fluoxetine was significantly superior to placebo at weeks 2,5,7, and 9 and weeks 2, 3, 7, and 9, respectively (p < .05).
Response was prospectively defined as a 30% or greater improvement in CDRS-R score. By this definition, the difference in the percentage of patients responding to treatment (fluoxetine: 65.1 %; placebo: 53.5%) was not significant (p = .093) (Table 4A) family history of depression (p = .809). A comparison of results with response ddLned over a range from~20% to~70% reduction in CORS-R score (Table 4A) indicates fluoxetine would be significantly superior to placebo if response had been defined as~20%,~40%,~50%, or~60% reduction in CDRS-R total score. Half of all fluoxetine-treated patients (52.3%) were rated much or very much improved (CGI-Improvement score of 1 or 2) compared with about a third of placebotreated patients (36.8%, p = .028). Fluoxetine-treated patients also had significa.ntly greater improvement in CGISeverity score than did placebo-trea.ted patients (p < .001) ( Table 3 ). There was no significant therapy by subgroup interaction for mean CGI-Improvement score based on age caregory (p = .959), gender (p = .379), or family history of depression (p =.290).
Mean improvement in HAMA score was not significantly different between Huoxetine-and placebo-treated patients (-4.8 ± 5.2 and -3.7 ± 5.2, respectively; p = .115). The finding that the 95%, confidence interval of the difference between trearment groups in mean change in HAMA score spans zero confirms that the two treatment groups did not separate significantly on mean improvement in HAMA score. Fluoxetine-treated patients showed significantly greater improvemenr rhan placebo-treated parients in CGI-Severity and MAORS scores, but not GAP score (Table 3 ). The effect size for fluoxetine is medium for the CGI-Severity scale, but small for the GAF scale. There were no significant differences between treatment groups in improvement in BOI score (fluoxetine: -4.6 ± 8.2; placebo: -5.3 ± 7.8;p = .700) or COl score (fluoxetine: -2.4 ± 9.0; placebo: -2.8 ± 6.8;p = .822).
Safety
Headache was the only nonsolicited adverse event reponed significantly more often by fluoxetine-treated patients than by placebo-treated patients (p = .017). Of interest, there was no significant difference between treatment groups in the number of patients reporting headaches on the Side Effects Checklist (p = .273). No items on the checklist occurred significantly more often in the f1uoxe-tine treatment group, although trouble with paying attention (p = .088) and with dizziness (p = .092) trended in that direction. The only statistically significant difference between treatment groups was for trouble pronouncing words (p = .015), which was associated with placebo. No clinically relevant treatment differences in solicited or nonsolicited treatment-emergent adverse events were observed among subgroups based on age category, gender, or family history of depression during the 9 weeks of this study.
One fluoxetine-treated patient and four placebo-treated patients experienced serious adverse events during the 9-week treatment period. Two patients experienced serious adverse events requiring hospitalization, but they did not leave the study: a fluoxetine-treated patient experienced swollen tonsils and a placebo-treated patient experienced abdominal pain and appendicitis. Three patients, all receiving placebo, experienced adverse events requiring hospitalization and causing them to discontinue their participation in the study (kidney infection, aggressive behavior, and self-mutilatory behavior).
Ninety (82.6%) fluoxetine-and 68 (61.8%) placebocreated patients completed the 9-week study period. This difference was significant (p = .001). There was no significant difference between treatment groups for any individual disconcinuation reason, although there was a trend toward significance for patient decision patients, tespectively;p = .408). Eleven patients discontinued because of nonserious adverse events. Among placebotreated patients, one each discontinued for rash, abdominal pain, alopecia, anxiety, dizziness, and headache (a total of six patients). Among fluoxetine-treated patients, one each discominued for rash, agitation, constipation, hyperkinesia, and manic reaction (a total of five patients). Throughout the 9 weeks of acute treatment, one f1uoxetine-treated patient (0.9%) experienced manic reaction. No placebo-treated patients experienced manic reaction, but this difference between treatment groups was not statistically significant.
There were no statistically significant differences between treatment groups for changes from baseline in vital signs, including sitting heart rate, sitting systolic blood pressure, sitting diastolic blood pressure, or temperature. Other safety measures, including laboratory tests and ECGs, were performed at a later phase of this study and will be included in future reports.
DISCUSSION
F1uoxetine was well tolerated and effective in a double-blind, placebo-controlled study evaluating 9 weeks of acute therapy with fluoxetine 20 mg daily in 219 child and adolescent outpatients with MOD. Fluoxetine 20 mg daily was more effective than placebo for the treatment of depression as demonstrated by significantly greater improvement in the CORS-R score. During the first week of treatment, fluoxetine-treated patients received 10 mg of fluoxetine daily. Since fluoxetine was statistically significantly superior to placebo within 1 week, it is possible that 10 mg daily may be an effective dose for MOD in some young patients. Further study is necessary to confirm this finding.
Fluoxetine was associated with statistically significantly greater improvement at endpoint in all four CORS-R subscores than was placebo. Fluoxetine was also significantly superior to placebo on global measures of improvement (CGI-Improvement) and disease severity (CGI-Severity). Significantly more fluoxetine-treated than placebo-treated patients met remission criteria at endpoint.
A statistically significantly greater number of fluoxetine-treated patients than placebo-treated patients had CORS-R score improvements of greater than or equal to 20%, 40%, 50%, or 60%. The same was not true at 30% (p = .093).
A review of the literature using CORS-R as a measure of treatment effectiveness indicates that a standard definition of response for CORS-R does not exist. Many studies examined mean change in CORS-R and did not use a predefined threshold of improvement to categorize patients as responders or reactors (Bernstein et al., 2000; Emslie et aI., 1997; Ghaziuddin et aI., 1996; Mandoki et al., 1997; Weisz et aI., 1997) .
Rintelmann and colleagues (1996) used a 20% or greater improvement in CORS-R to define a patient population they called "reactors." Examination of the data suggests differences in how percentages were calculated between that study and this one. Our original calculations did not correct for the fuct that the CORS-Rhas a minimum score of 17, not O. We used the formula: percent change equals (baseline score -endpoint score)/baseline score. Rintelmann and colleagues appear to have used a formula that does correct for rhe nonzero minimum score of the CORS-R: percent change equals ([baseline score -17] -[endpoint score -17])/(baseline score -17). That formula is likely to be a better method of assessing change than the one EFFICACY OF FLUOXETINE IN PEDIATRIC MOD used in the prospective definition of response for this study. For instance, using our original method, a patient with an initial score of 45 at baseline with maximal improvement at endpoint (a CORS-R score of 17) would have a calculated percentage improvement of 62%. Using the formula of Rintelmann and colleagues, the fact that this patient had achieved the maximum possible improvement would be reflected by a calculated percentage improvement of 100%. If the formula of Rintelmann and colleagues is used to calculate the percentage change in CORS-R from the data of this study, statistically significantly more fluoxetine-treated patients than placebo-treated patients had CORS-Rscores that decreased~20%,~30%,~40%, 50%,~60%, and~70% (p < .05) ( Table 4B ).
All study patients met DSM-IV criteria for MOD; however, the study population contained a larger percentage of patients with low BOI and COl scores than might be expected among American youths with MOD. (Roberts and colleagues [1991] reported that approximately 84% of high school students with current MDD and 20% of high school students without current MOD will score above the cut points of 11 for girls and 15 for boys.) The reason for the comparatively low BOI and COl scores in our study population is unclear. It is possible that the reading levels of these measures-third [Q fifth grade for the COl and eighth grade for the BOlas well as the fact that one third of our study population had comorbid AOHO, may have played a role. The low baseline scores for these measures suggest that changes in these scores may not have been an accurate assessment of change in depressive condition for this patient group. Because the initial scores were low, it is not surprising that there were no statistically significant differences between treatment groups in improvement on COl and BOI scores during this study. These results are similar to those reported previously (Emslie et aI., 1997) .
Assessment by MAORS was included in this study as an exploratory measure. The mean changes in MAORS score in this study are consistent with rhe mean changes in CORS-R scores. Further study is necessary to determine the true validity of MAORS as a measure of depressive symptoms in children and adolescents.
This report contains data from the first phase of a longer clinical trial. Laboratory and ECG tests were performed at baseline, at 19 weeks and at 51 weeks, but not during the 9-week fixed-dose phase of the trial reported here. Those data will be reported in full in subsequent reports.
). AM. ACAD. CHILD ADOLESC. PSYCHIATRY. 41:10, OCTOBER 2002 :, :11; :' Throughout this study period, fluoxetine 20 mg/day was well tolerated by children and adolescents; significantly fewer fluoxetine-than placebo-treated patients discominued their participation in the study. Only one nonsolicited adverse event (headache) was reported significantly more often by fluoxetine-treated patients than by patients receiving placebo. No solicited adverse event occurred more often in fluoxerine-treated patients than in placebo-treated patients. This is consistent with the safety profile observed for fluoxetine in treatment of obsessive-compulsive disorder in children and adolescents (Geller et aI., 2001) .
Limitations
Patients who enrolled in this study were predominantly white. While no significant differences between whites and nonwhites were observed, the number of nonwhites was too small to conclude that fluoxetine efficacy and safety arc constant across ethnic groups. Information about patients' socioeconomic status was not collected during this trial; therefore, we cannot conclude that fluoxetine efficacy and safety were constant across socioeconomic groups.
Clinical Implications
The present study is the second randomized, controlled, double-blind clinical trial of fluoxetine for acute treatment of children and adolescents with MDD. The efficacy and safety results, consistent with those of an earlier clinical trial (Emslie et aI., 1997) , indicate fluoxetine 20 mg is a well-tolerated and effective treatment for depression in children and adolescenrs.
